About M3DC

M3DC is an independent scientific management and consulting organization specialized in:
1. the creation and management of large, multidisciplinary and cross-national research and development projects in drug discovery and drug development
2. networking with the drug development experts at the local, national and transnational community level
The individual company was founded in 2013 in Chêne-Bourg/Geneva, Switzerland, by Michel Dreano.
M. Dreano serves as Scientific Coordinator for a large pharmaceutical organization involved in the European-funded FP7 Project “Development of Novel Nanotechnology the security under the lawcoursework help, dissertation, documents writing support http://writemyessayrapid.com/editing-service/ assignmenthelpis most readily useful uk’s assignment publishing service company. wherever our with Based Diagnostic Systems for Rheumatoid Arthritis and Osteoarthritis“ M3DC is well connected to academic and industrial experts in the field of nanotechnology, nanomedicine, neurosciences, oncology, metabolic, endocrinology, arthritis essentially in Europe.
M. Dreano has managed for his former employers, and Merck Serono, many strategic collaborations and partnerships with academic institutions, research contract organizations, biotechs or large pharmaceutical organizations.
Operating from Geneva, Switzerland, M3DC substantially increases the value coursework writing of a project by efficiently managing its translation from the lab to clinical proof of concept with industrial applications always in sight. This responds to the current needs of many drug dissertation help sponsors who tends to outsource most of their projects to contain in-house spending. M3DC is able to operate within a formal association of partners with specialised expertise in niche areas, all sharing an extensive experience in the Life Science industry. Furthermore, M3DC can count on a wide network of highly reliable professionals who have already expressed their availability to support every aspects of this project. This network is of particular help to effectively streamline M3DC services. Such an approach greatly reduces costs and operational problems for young but also large pharmaceutical companies.